PMID- 24285106
OWN - NLM
STAT- MEDLINE
DCOM- 20140801
LR  - 20181202
IS  - 0391-1977 (Print)
IS  - 0391-1977 (Linking)
VI  - 38
IP  - 4
DP  - 2013 Dec
TI  - Impact of cinacalcet hydrochloride in clinical management of primary 
      hyperparathyroidism in multiple endocrine neoplasia type 1.
PG  - 389-94
AB  - AIM: Primary hyperparathyroidism (PHPT) is one of main cause of morbidity in 
      patients with multiple endocrine neoplasia type 1 (MEN1). Medical therapy with 
      cinacalcet-hydrochloride may modify the therapeutic strategy of MEN1 related 
      PHPT. We present an experience with cinacalcet-hydrochloride in two patients with 
      MEN1 PHPT. METHODS: The study included two MEN1 patients belonging to the same 
      family (a 50-year-old woman and her daughter aged 20 years) with PHPT secondary 
      to multiple involvement of parathyroid glands and other MEN1 related tumors. As 
      both patients refused to undergo parathyroid surgery, we decided to start medical 
      treatment with cinacalcet at the dose of 30 mg/day, which was the first treatment 
      for the youngest patient, while the oldest had already been treated with partial 
      parathyroidectomy. Serum concentrations of PTH, calcium and phosphorus, 24-h 
      urine calcium-to-creatinine ratio and renal-threshold-phosphate concentration 
      were evaluated before and after therapy. RESULTS: Serum calcium and PTH levels 
      were normalized after 1 and 6 months of therapy, respectively, and 60 and 54 
      months after the beginning of cinacalcet remained normal. Hypercalciuria, 
      hypophosphoremia and renal-threshold-phosphate normalized during therapy with 
      cinacalcet. At ultrasonography, parathyroid nodular lesion remained unchanged. 
      Cinacalcet was well tolerated without occurrence of side effects. CONCLUSION: 
      Cinacalcet seems to be highly effective in controlling PHPT in patients with MEN1 
      either in naive patients or in those with postsurgical recurrence. If cinacalcet 
      will be confirmed to ensure a long-time control of PHPT or even to prevent the 
      development and progression of PHPT, this may led to modify the therapeutic 
      strategy of MEN1 PHPT.
FAU - Del Prete, M
AU  - Del Prete M
AD  - Department of Molecular and Clinical Endocrinology and Oncology, "Federico II" 
      University, Naples, Italy - michidelpre@gmail.com.
FAU - Marotta, V
AU  - Marotta V
FAU - Ramundo, V
AU  - Ramundo V
FAU - Marciello, F
AU  - Marciello F
FAU - Di Sarno, A
AU  - Di Sarno A
FAU - Esposito, R
AU  - Esposito R
FAU - Carratu, A C
AU  - Carratu AC
FAU - De Luca Di Roseto, C
AU  - De Luca Di Roseto C
FAU - Di Somma, C
AU  - Di Somma C
FAU - Colao, A
AU  - Colao A
FAU - Faggiano, A
AU  - Faggiano A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Minerva Endocrinol
JT  - Minerva endocrinologica
JID - 8406505
RN  - 0 (Biomarkers)
RN  - 0 (Calcimimetic Agents)
RN  - 0 (Naphthalenes)
RN  - 0 (Parathyroid Hormone)
RN  - 27YLU75U4W (Phosphorus)
RN  - SY7Q814VUP (Calcium)
RN  - UAZ6V7728S (Cinacalcet)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood
MH  - Calcimimetic Agents/*therapeutic use
MH  - Calcium/blood
MH  - Cinacalcet
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hyperparathyroidism, Primary/blood/diagnosis/*drug therapy/*genetics/surgery
MH  - Middle Aged
MH  - Mothers
MH  - Multiple Endocrine Neoplasia Type 1/*complications
MH  - Naphthalenes/*therapeutic use
MH  - Nuclear Family
MH  - Parathyroid Hormone/blood
MH  - Pedigree
MH  - Phosphorus/blood
MH  - Treatment Outcome
EDAT- 2013/11/29 06:00
MHDA- 2014/08/02 06:00
CRDT- 2013/11/29 06:00
PHST- 2013/11/29 06:00 [entrez]
PHST- 2013/11/29 06:00 [pubmed]
PHST- 2014/08/02 06:00 [medline]
AID - R07Y2013N04A0389 [pii]
PST - ppublish
SO  - Minerva Endocrinol. 2013 Dec;38(4):389-94.